Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

Zhang J-Y. et al, (2022), Nature Communications, 13

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

Dunger DB. et al, (2022), Trials, 23

Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients

Zhang J-Y. et al, (2022)

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

Jarvis LB. et al, (2021), Commun Biol, 4

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.

Robertson CC. et al, (2021), Nature genetics

Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus

Trzupek D. et al, (2021), Wellcome Open Research, 6, 149 - 149

Therapeutically expanded human regulatory T-cells are super- suppressive due to HIF1A induced expression of CD73.

Jarvis L. et al, (2020)

T1DBase: Community website for type 1 diabetes research

Hulbert EM. et al, (2006), DIABETES, 55, A251 - A251

Include forthcoming?